DAMGO, tritiated at the tyrosyl 3,5 poisition. DAMGO is a synthetic opioid analog with high specificity for the μ-opioid receptor.
For research use only. Not for use in diagnostic procedures
DAMGO is a synthetic agonist with high selectivity for the mu-opioid receptor (MOR). These receptors are a group of GPCRs that are involved in analgesia, and are potential drug targets for drug addiction.
We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (Bmax), dissociation constants (Kd), association and dissociation rates (kon and koff), and inhibitor constants (Ki) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.
Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.
References for NET902:
Molecular Weight |
513.7
|
---|
Application |
Drug Discovery & Development
|
---|---|
Brand |
NEN Radiochemicals
|
Detection Method |
Radiometric
|
Label Position |
Nominally Labeled
|
One Unit Contains |
250.0 µCi
|
Radionuclide |
3H
|
Radioisotope |
H-3
|
Receptor Type |
Opioid
|
Shipping Conditions |
Shipped in Dry Ice
|
Special Ordering Information |
This is a radioactive product - shipping address must have a license to receive radioactive materials.
|
Therapeutic Area |
CNS & Neurologic
Inflammation
Pain
|
Unit Size |
250 µCi
|
Are you looking for technical documents related to the product? We have categorized them in dedicated sections below. Explore now.
We are here to answer your questions.